Baidu
map

PLoS Comput Biol:全新发现:影响炎症治疗的两个关键分子

2017-04-21 sunshine2015 来宝网

【科学家鉴定出两种抑制炎症反应的分子】科学家已经确定了可以作为慢性炎性疾病的潜在治疗方法的两种小分子靶点。根据PLOS计算生物学杂志发表的论文,研究人员使用他们开发的新的药物筛选方法分析了这两个分子。称为T23和T8的两种分子抑制被叫作肿瘤坏死因子(TNF)的蛋白质的功能,其参与诸如类风湿性关节炎,克罗恩病,牛皮癣,多发性硬化等疾病的炎症过程。抑制TNF功能的药物被认为是最有效的对抗这些疾病的方法


科学家已经确定了可以作为慢性炎性疾病的潜在治疗方法的两种小分子靶点。根据PLOS计算生物学杂志发表的论文,研究人员使用他们开发的新的药物筛选方法分析了这两个分子。

称为T23和T8的两种分子抑制被叫作肿瘤坏死因子(TNF)的蛋白质的功能,其参与诸如类风湿性关节炎,克罗恩病,牛皮癣,多发性硬化等疾病的炎症过程。抑制TNF功能的药物被认为是最有效的对抗这些疾病的方法。然而,并不是所有的患者都对这些药物做出了反应,并且随着时间的推移,它们的功效可能会消失。

为了帮助发现更好的TNF抑制药物,Georgia Melagraki和来自希腊和塞浦路斯的同事开发了一种新的基于计算机的药物筛选平台。该平台包含TNF和另一种称为RANKL的蛋白质之间共同的专有分子性质,RANKL也参与慢性炎性疾病。

研究人员开发了基于先进计算工具的平台。然后使用该平台来实际筛选近15,000个具有未知活性的小分子,并预测它们与TNF和RANKL蛋白的相互作用; 具体来说,就是小分子可能如何破坏导致这些关键蛋白质的三聚和活化的蛋白质相互作用(PPI)。 “这个虚拟实验从成千上万的候选者中发现了九种有希望的分子,”研究共同作者NovaMechanics有限公司的Antreas Afantitis说道。

为了进一步评估其潜力,科学家们研究了9个小分子与实际实验中的TNF和RANKL的相互作用。在9个分子中,T23和T8表现为特别强的TNF抑制作用。两个分子都与TNF和RANKL结合,阻止它们与其他蛋白质正确发生相互作用。两者在人体中也可能引起毒副作用。

亚历山大·弗莱明(Alexander Fleming)生物医学科学研究中心的研究人员,即研究共同作者George Kollias说:“T23和T8可以进一步优化,以开发一系列炎症,自身免疫和骨丢失疾病的治疗方法”。同时,新的虚拟药物筛选方法可以发现其他有希望的TNF抑制剂,并且可以进行修改以寻找治疗其他疾病的潜在方法。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917454, encodeId=ffca191e45404, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 13 07:40:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005137, encodeId=fb14200513e0f, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Fri Jun 23 20:40:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767105, encodeId=be201e6710533, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 29 21:40:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921166, encodeId=48561921166f8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri Jun 09 02:40:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189548, encodeId=0b6f18954802, content=希望将来能应用于患者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Apr 22 06:42:03 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189486, encodeId=ab8018948666, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Apr 21 23:26:23 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-07-13 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1917454, encodeId=ffca191e45404, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 13 07:40:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005137, encodeId=fb14200513e0f, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Fri Jun 23 20:40:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767105, encodeId=be201e6710533, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 29 21:40:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921166, encodeId=48561921166f8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri Jun 09 02:40:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189548, encodeId=0b6f18954802, content=希望将来能应用于患者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Apr 22 06:42:03 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189486, encodeId=ab8018948666, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Apr 21 23:26:23 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1917454, encodeId=ffca191e45404, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 13 07:40:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005137, encodeId=fb14200513e0f, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Fri Jun 23 20:40:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767105, encodeId=be201e6710533, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 29 21:40:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921166, encodeId=48561921166f8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri Jun 09 02:40:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189548, encodeId=0b6f18954802, content=希望将来能应用于患者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Apr 22 06:42:03 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189486, encodeId=ab8018948666, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Apr 21 23:26:23 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1917454, encodeId=ffca191e45404, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 13 07:40:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005137, encodeId=fb14200513e0f, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Fri Jun 23 20:40:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767105, encodeId=be201e6710533, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 29 21:40:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921166, encodeId=48561921166f8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri Jun 09 02:40:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189548, encodeId=0b6f18954802, content=希望将来能应用于患者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Apr 22 06:42:03 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189486, encodeId=ab8018948666, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Apr 21 23:26:23 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1917454, encodeId=ffca191e45404, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 13 07:40:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005137, encodeId=fb14200513e0f, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Fri Jun 23 20:40:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767105, encodeId=be201e6710533, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 29 21:40:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921166, encodeId=48561921166f8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri Jun 09 02:40:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189548, encodeId=0b6f18954802, content=希望将来能应用于患者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Apr 22 06:42:03 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189486, encodeId=ab8018948666, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Apr 21 23:26:23 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-22 大爰

    希望将来能应用于患者!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1917454, encodeId=ffca191e45404, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 13 07:40:00 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005137, encodeId=fb14200513e0f, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Fri Jun 23 20:40:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767105, encodeId=be201e6710533, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 29 21:40:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921166, encodeId=48561921166f8, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Fri Jun 09 02:40:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189548, encodeId=0b6f18954802, content=希望将来能应用于患者!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Apr 22 06:42:03 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189486, encodeId=ab8018948666, content=签到学习了很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/A3E53E62691178E2F18D7B999FD22131/100, createdBy=f44d2003846, createdName=Chongyang Zhang, createdTime=Fri Apr 21 23:26:23 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 Chongyang Zhang

    签到学习了很多

    0

相关资讯

PLOS COMPUT BIOL:发现影响炎症治疗的两个关键分子

科学家已经确定了可以作为慢性炎性疾病的潜在治疗方法的两种小分子靶点。根据PLOS计算生物学杂志发表的论文,研究人员使用他们开发的新的药物筛选方法分析了这两个分子。

Neurology:单相脱髓鞘延缓儿童大脑发育

后天脱髓鞘综合征会影响儿童大脑发育水平,该疾病进程可能受到炎症和其他因素的共同影响

Nature Immunology:游走在抗炎和促炎间的巨噬细胞

这一研究更加现实的解释了巨噬细胞在不同的促炎和抗炎功能上的弹性。说明了巨噬细胞通过IFN-γ和IL-4同时刺激,维持促炎和抗炎功能上的弹性,有维持一定的基本细胞功能。又因为IFN-γ和IL-4刺激而激活的下游Stat1和Stat6蛋白的相互竞争抑制,维持动态平衡,又可以通过调控快速切换不同功能。这一研究对开发针对巨噬细胞的肿瘤免疫疗法有重要意义。

NAT MICROBIOL:生物物理所等解析调控肠道免疫炎症平衡的新机制

由中国科学院生物物理研究所感染与免疫重点实验室果蝇研究团队完成的论文 Bap180/Baf180 is required to maintain homeostasis of intestinal innate immune response in Drosophila and mice 以 article 的形式,于 4 月 18 日发表在最新一期的《自然 - 微生物学》(Nature Micr

儿童卒中前比成人更易感头痛

最新研究表明,儿童在缺血性卒中前比成人更容易头痛。缺血性卒中是由大脑中的血管堵塞引起的。Lori Billinghurst博士说:“如果一个儿童出现头痛,且伴有乏力,或者面部、手臂或下肢的麻木,或者行走,讲话及视力出现改变,应考虑脑卒中。”宾夕法尼亚大学神经病学和费城儿童医院的临床助理教授Billinghurst 说,“可能需要紧急脑成像区分偏头痛与卒中先兆”。但儿童卒中是非常罕见的,孩子从出生到

Immunity:谷胱甘肽调节T细胞免疫力

这项研究揭示了谷胱甘肽如何调节T细胞免疫力的分子机制,为针对T细胞调节人机体免疫力和过免疫疾病提供了理论基础。

Baidu
map
Baidu
map
Baidu
map